Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis.
Szaflarski JP, Besson H, D'Souza W, Faught E, Klein P, Reuber M, Rosenow F, Salas-Puig J, Soto Insuga V, Steinhoff BJ, Strzelczyk A, Bourikas D, Daniels T, Floricel F, Friesen D, Laloyaux C, Villanueva V. Szaflarski JP, et al. Among authors: laloyaux c. J Neurol. 2024 Jun;271(6):3169-3185. doi: 10.1007/s00415-024-12253-z. Epub 2024 Mar 4. J Neurol. 2024. PMID: 38436680 Free PMC article.
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, Rosenow F, Sirven JI, Smith B, Stern JM, Toledo M, Zipfel PA, Villanueva V. Steinhoff BJ, et al. Among authors: laloyaux c. Epilepsy Behav. 2021 May;118:107939. doi: 10.1016/j.yebeh.2021.107939. Epub 2021 Apr 8. Epilepsy Behav. 2021. PMID: 33839453 Free article. Review.
Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
Brandt C, Dimova S, Elmoufti S, Laloyaux C, Nondonfaz X, Klein P. Brandt C, et al. Among authors: laloyaux c. Epilepsy Behav. 2023 Jan;138:108967. doi: 10.1016/j.yebeh.2022.108967. Epub 2022 Nov 23. Epilepsy Behav. 2023. PMID: 36435010 Free article. Clinical Trial.
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
Villanueva V, Laloyaux C, D'Souza W, Faught E, Klein P, Reuber M, Rosenow F, Salas-Puig J, Insuga VS, Strzelczyk A, Szaflarski JP, Chinn C, Daniels T, Floricel F, Friesen D, Sendersky V, Besson H, Steinhoff BJ. Villanueva V, et al. Among authors: laloyaux c. CNS Drugs. 2023 Sep;37(9):819-835. doi: 10.1007/s40263-023-01033-4. Epub 2023 Sep 9. CNS Drugs. 2023. PMID: 37684497 Free PMC article. Review.
Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies.
Faught E, Besson H, D'Souza W, Klein P, Reuber M, Rosenow F, Salas-Puig J, Insuga VS, Steinhoff BJ, Strzelczyk A, Szaflarski JP, Bourikas D, Daniels T, Floricel F, Friesen D, Laloyaux C, Villanueva V. Faught E, et al. Among authors: laloyaux c. Epilepsy Behav. 2024 Sep;158:109922. doi: 10.1016/j.yebeh.2024.109922. Epub 2024 Jul 5. Epilepsy Behav. 2024. PMID: 38970892 Free article.
21 results